Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products

April 20, 2026 at 09:58 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

2149611199 1 1 Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products

The Company’s Health Canada-licensed GMP psychedelic manufacturing platform ready to serve emerging demand for ibogaine, a naturally occurring alkaloid under investigation for opioid use disorder, PTSD, and traumatic brain injury Vancouver, British Columbia–(April 20, 2026) – Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) (FSE: 8BN) (the “Company” or “Optimi“), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug … Continue reading

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Symbol	Price	Change (%)
AMZN	259.45	-1.86 (-0.71%)
AAPL	310.03	+4.44 (1.45%)
AMD	484.39	-21.61 (-4.27%)
BAC	64.23	+0.34 (0.53%)
GOOG	341.28	-0.17 (-0.05%)
META	543.67	-25.30 (-4.45%)
MSFT	481.63	+1.28 (0.27%)
NVDA	219.74	-5.27 (-2.34%)
ORCL	142.79	-3.86 (-2.63%)
TSLA	336.87	-2.43 (-0.72%)

Symbol

Price

Change (%)

AMZN

259.45

-1.86 (-0.71%)

AAPL

310.03

+4.44 (1.45%)

AMD

484.39

-21.61 (-4.27%)

BAC

64.23

+0.34 (0.53%)

GOOG

341.28

-0.17 (-0.05%)

Optimi Health Launches Ibogaine Initiative as U.S. Executive Order Signals Pathway for Psychedelic Drug Products

More News

Recent Quotes